Top doctors raised concerns about domestically made drugs, saying Beijing’s effort to lower costs is sacrificing quality.

Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.

In an effort to safeguard fair market competition and protect consumer interests, the State Council's anti-monopoly ...

A Chinese court's decision to revise the ruling in a drug case involving a former associate chemistry professor — dubbed the "Chinese version of Breaking Bad" — reflects the country's commitment to ...

Zai Lab (ZLAB) announced that China’s National Medical Products Administration, NMPA, has accepted the New Drug Application, NDA, for KarXT for ...

Shares of Waters Corp . (NYSE: NYSE: WAT) tumbled 5% today, as the U.S. Commerce Department announced new export controls on biotechnology equipment, citing national security concerns. The new ...

The aPKCi inhibitor platform is a novel, potential high-potency, specific, drug candidate with applications in oncology ...

Zai Lab (NASDAQ:ZLAB) announced Wednesday it would seek marketing approval for its cervical cancer therapy Tivdak (tisotumab ...

A recently unsealed application for a federal wiretap offers glimpses of the serpentine path of a major drug investigation.

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS ® (savolitinib) has been granted approval by the China National Medical ...

In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer, in ...

In the field of value-based medicine (VBM), the focus is increasingly shifting towards integrating innovative healthcare solutions that are both ...